Bangladesh-based clinical research institute delivering vaccine trials and AI-assisted disease screening in South Asian LMIC field settings.
ICDDR,B is a Bangladesh-based international research institute specializing in infectious and non-communicable disease research in low- and middle-income country (LMIC) settings. Their core work involves conducting clinical trials and field studies in South Asia, where they provide access to high-burden patient populations that are essential for validating vaccines and health interventions at scale. In H2020, they served as a clinical field site and research partner for vaccine development against diarrhoeal pathogens (Shigella, ETEC) and for testing AI-assisted cervical cancer screening protocols in community settings. Their primary value to international consortia is real-world clinical research infrastructure in a high-disease-burden environment that European institutions cannot replicate domestically.
SHIGETECVAX (2019–2026) centres on early clinical development of a live attenuated combination vaccine against two major diarrhoeal pathogens, directly mapping to ICDDR,B's institutional mandate.
SHIGETECVAX (EUR 1.9M) involves clinical trial execution for an experimental enteric vaccine, indicating ICDDR,B holds regulated trial capacity in a South Asian field site.
PRESCRIP-TEC (2021–2024) focuses on HPV-test-based screening and protocol uptake in community settings, representing a clear move into non-communicable disease prevention.
PRESCRIP-TEC lists artificial intelligence and protocol uptake as keywords alongside cost-effectiveness analysis, suggesting ICDDR,B is testing AI-based screening tools in real-world low-resource deployments.
ICDDR,B's H2020 entry was firmly rooted in its founding mission — enteric infectious disease — through the SHIGETECVAX vaccine trial targeting Shigella and ETEC, two leading causes of diarrhoeal mortality. By 2021, their second project shifted entirely to non-communicable disease, specifically AI-guided cervical cancer screening and HPV-based prevention in community settings. This is a meaningful pivot: from pathogen-specific vaccine R&D toward digital health tools and cancer prevention programs, both areas of growing global health priority in LMICs.
ICDDR,B appears to be broadening from its infectious disease core toward AI-enabled, community-based prevention of non-communicable diseases — making them an increasingly relevant partner for digital health consortia targeting underserved populations in South Asia and beyond.
ICDDR,B has participated exclusively as a consortium partner — never as a project coordinator — across both H2020 projects. This pattern is consistent with their role as a specialized field site provider: European-led consortia recruit them for South Asian clinical access, patient populations, and regulatory familiarity, rather than for project management. Working with them means engaging a well-scoped specialist who brings geographic and epidemiological access that is otherwise unavailable to EU-based teams.
ICDDR,B has built a network of 22 unique consortium partners across 11 countries through just two projects, suggesting their participation attracts large, internationally distributed consortia. Their Bangladesh base gives them a distinct geographic profile within European research networks, where South Asian field sites are rare.
ICDDR,B occupies a near-unique position in H2020 health research as one of very few South Asian research institutions with clinical trial infrastructure capable of executing EU-funded RIA projects. For any consortium targeting high-burden infectious disease or LMIC health innovation, they provide irreplaceable access to Bangladeshi patient cohorts and field deployment conditions. Their institutional name reflects a decades-long specialization that no European partner can substitute.
